JP2011518196A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011518196A5 JP2011518196A5 JP2011505265A JP2011505265A JP2011518196A5 JP 2011518196 A5 JP2011518196 A5 JP 2011518196A5 JP 2011505265 A JP2011505265 A JP 2011505265A JP 2011505265 A JP2011505265 A JP 2011505265A JP 2011518196 A5 JP2011518196 A5 JP 2011518196A5
- Authority
- JP
- Japan
- Prior art keywords
- pp2a
- compound
- item
- formula
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 198
- 238000000034 method Methods 0.000 claims description 48
- 125000000217 alkyl group Chemical group 0.000 claims description 37
- 230000000694 effects Effects 0.000 claims description 35
- 229910052736 halogen Inorganic materials 0.000 claims description 27
- 150000002367 halogens Chemical class 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 25
- 230000011987 methylation Effects 0.000 claims description 24
- 238000007069 methylation reaction Methods 0.000 claims description 24
- 125000004122 cyclic group Chemical group 0.000 claims description 22
- 125000005842 heteroatom Chemical group 0.000 claims description 16
- 102000013498 tau Proteins Human genes 0.000 claims description 15
- 108010026424 tau Proteins Proteins 0.000 claims description 15
- 230000004770 neurodegeneration Effects 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 230000026731 phosphorylation Effects 0.000 claims description 14
- 238000006366 phosphorylation reaction Methods 0.000 claims description 14
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 13
- 125000003342 alkenyl group Chemical group 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 229920006395 saturated elastomer Polymers 0.000 claims description 11
- 125000004417 unsaturated alkyl group Chemical group 0.000 claims description 11
- 150000001720 carbohydrates Chemical class 0.000 claims description 10
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 9
- 208000032859 Synucleinopathies Diseases 0.000 claims description 9
- 150000001491 aromatic compounds Chemical class 0.000 claims description 9
- 230000017858 demethylation Effects 0.000 claims description 9
- 238000010520 demethylation reaction Methods 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 230000005856 abnormality Effects 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 206010012289 Dementia Diseases 0.000 claims description 5
- 230000002159 abnormal effect Effects 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 201000010374 Down Syndrome Diseases 0.000 claims description 3
- 102100040243 Microtubule-associated protein tau Human genes 0.000 claims description 3
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 3
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 3
- 206010034010 Parkinsonism Diseases 0.000 claims description 3
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 3
- 210000000349 chromosome Anatomy 0.000 claims description 3
- 230000001054 cortical effect Effects 0.000 claims description 3
- 230000007850 degeneration Effects 0.000 claims description 3
- 230000003412 degenerative effect Effects 0.000 claims description 3
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 3
- 210000003523 substantia nigra Anatomy 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 102000006478 Protein Phosphatase 2 Human genes 0.000 claims 16
- 108010058956 Protein Phosphatase 2 Proteins 0.000 claims 16
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims 7
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims 7
- 230000001594 aberrant effect Effects 0.000 claims 6
- 102000003802 alpha-Synuclein Human genes 0.000 claims 6
- 108090000185 alpha-Synuclein Proteins 0.000 claims 6
- 102000016397 Methyltransferase Human genes 0.000 claims 4
- 108060004795 Methyltransferase Proteins 0.000 claims 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 4
- 230000006951 hyperphosphorylation Effects 0.000 claims 4
- 239000000758 substrate Substances 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims 4
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 claims 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims 2
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims 2
- 206010044688 Trisomy 21 Diseases 0.000 claims 2
- 235000004883 caffeic acid Nutrition 0.000 claims 2
- 229940074360 caffeic acid Drugs 0.000 claims 2
- 229960001948 caffeine Drugs 0.000 claims 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims 2
- 235000001368 chlorogenic acid Nutrition 0.000 claims 2
- 229940074393 chlorogenic acid Drugs 0.000 claims 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims 2
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 claims 2
- 210000002569 neuron Anatomy 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 101000741929 Caenorhabditis elegans Serine/threonine-protein phosphatase 2A catalytic subunit Proteins 0.000 description 76
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 241000533293 Sesbania emerus Species 0.000 description 6
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 6
- -1 Aminoiminomethyl Chemical group 0.000 description 5
- 101710188297 Trehalose synthase/amylase TreS Proteins 0.000 description 5
- 230000001747 exhibiting effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 0 CC=C(*C=C1*N)C1=CC=C Chemical compound CC=C(*C=C1*N)C1=CC=C 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 235000008100 Ginkgo biloba Nutrition 0.000 description 3
- 244000194101 Ginkgo biloba Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 244000187129 Bacopa monnieria Species 0.000 description 2
- 235000015418 Bacopa monnieria Nutrition 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- 235000013162 Cocos nucifera Nutrition 0.000 description 2
- 244000060011 Cocos nucifera Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 235000017309 Hypericum perforatum Nutrition 0.000 description 2
- 244000141009 Hypericum perforatum Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 244000090896 Nigella sativa Species 0.000 description 2
- 235000016698 Nigella sativa Nutrition 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 235000021028 berry Nutrition 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000001711 nigella sativa Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical group ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- UFDJZEDCUUVYFF-OAHLLOKOSA-N (2r)-n'-hydroxy-n-[2-(1h-indol-3-yl)ethyl]-n-methyl-2-(2-methylpropyl)butanediamide Chemical compound C1=CC=C2C(CCN(C)C(=O)[C@@H](CC(=O)NO)CC(C)C)=CNC2=C1 UFDJZEDCUUVYFF-OAHLLOKOSA-N 0.000 description 1
- JARJTAYDOHOWDP-HNNXBMFYSA-N (2s)-2-[[2-(1h-indol-3-yl)acetyl]amino]heptanoic acid Chemical compound C1=CC=C2C(CC(=O)N[C@@H](CCCCC)C(O)=O)=CNC2=C1 JARJTAYDOHOWDP-HNNXBMFYSA-N 0.000 description 1
- VJXXEAMTHWBHRX-UHFFFAOYSA-N 1-(3-ethyl-2-morpholin-4-ylpentyl)-3-[2-(1h-indol-3-yl)ethyl]urea Chemical compound C=1NC2=CC=CC=C2C=1CCNC(=O)NCC(C(CC)CC)N1CCOCC1 VJXXEAMTHWBHRX-UHFFFAOYSA-N 0.000 description 1
- QSGRXISNALKWNG-UHFFFAOYSA-N 1-methyl-n-(5-methylhexan-2-yl)indole-2-carboxamide Chemical compound C1=CC=C2N(C)C(C(=O)NC(C)CCC(C)C)=CC2=C1 QSGRXISNALKWNG-UHFFFAOYSA-N 0.000 description 1
- SKAIUNFJDDNFTO-UHFFFAOYSA-N 2-(1h-indol-3-yl)-n-(5-methylhexan-2-yl)acetamide Chemical compound C1=CC=C2C(CC(=O)NC(C)CCC(C)C)=CNC2=C1 SKAIUNFJDDNFTO-UHFFFAOYSA-N 0.000 description 1
- WCKCPHMBGYWMRF-UHFFFAOYSA-N 2-(1h-indol-3-yl)-n-(6-methylheptan-2-yl)acetamide Chemical compound C1=CC=C2C(CC(=O)NC(C)CCCC(C)C)=CNC2=C1 WCKCPHMBGYWMRF-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- BFSHNGNDWAZISU-UHFFFAOYSA-N 2-(5,6-dimethyl-1-benzofuran-2-yl)-n-(5-methylhexan-2-yl)acetamide Chemical compound CC1=C(C)C=C2OC(CC(=O)NC(C)CCC(C)C)=CC2=C1 BFSHNGNDWAZISU-UHFFFAOYSA-N 0.000 description 1
- KIFRZUYOEPSZNA-UHFFFAOYSA-N 2-(5-bromo-1h-indol-3-yl)-n-octadecyl-2-oxoacetamide Chemical compound C1=C(Br)C=C2C(C(=O)C(=O)NCCCCCCCCCCCCCCCCCC)=CNC2=C1 KIFRZUYOEPSZNA-UHFFFAOYSA-N 0.000 description 1
- MKSIYCASMUEVND-UHFFFAOYSA-N 2-(6-methoxy-1-benzofuran-2-yl)-n-(5-methylhexan-2-yl)acetamide Chemical compound COC1=CC=C2C=C(CC(=O)NC(C)CCC(C)C)OC2=C1 MKSIYCASMUEVND-UHFFFAOYSA-N 0.000 description 1
- LWUWTUNOEPKBFP-UHFFFAOYSA-N 2-(6-methoxy-1-benzofuran-2-yl)-n-(6-methylheptan-2-yl)acetamide Chemical compound COC1=CC=C2C=C(CC(=O)NC(C)CCCC(C)C)OC2=C1 LWUWTUNOEPKBFP-UHFFFAOYSA-N 0.000 description 1
- ISKLBALCRHZNGC-UHFFFAOYSA-N 2-ethyl-n-[2-(5-methoxy-1h-indol-3-yl)ethyl]hexanamide Chemical compound C1=C(OC)C=C2C(CCNC(=O)C(CC)CCCC)=CNC2=C1 ISKLBALCRHZNGC-UHFFFAOYSA-N 0.000 description 1
- LLUVOKGTTOXMGI-UHFFFAOYSA-N 2-ethyl-n-[2-(5-methyl-1h-indol-3-yl)ethyl]hexanamide Chemical compound C1=C(C)C=C2C(CCNC(=O)C(CC)CCCC)=CNC2=C1 LLUVOKGTTOXMGI-UHFFFAOYSA-N 0.000 description 1
- ULHDCXNVPILYCX-UHFFFAOYSA-N 3-(1h-indol-3-yl)-n-(5-methylhexan-2-yl)propanamide Chemical compound C1=CC=C2C(CCC(=O)NC(C)CCC(C)C)=CNC2=C1 ULHDCXNVPILYCX-UHFFFAOYSA-N 0.000 description 1
- LHQMNKYDIBSGOP-UHFFFAOYSA-N 3-(1h-indol-3-yl)-n-(6-methylheptan-2-yl)propanamide Chemical compound C1=CC=C2C(CCC(=O)NC(C)CCCC(C)C)=CNC2=C1 LHQMNKYDIBSGOP-UHFFFAOYSA-N 0.000 description 1
- 241000544312 Amoya Species 0.000 description 1
- 235000010870 Annona cherimola x Annona squamosa Nutrition 0.000 description 1
- 235000017401 Annona x atemoya Nutrition 0.000 description 1
- 244000137984 Annona x atemoya Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- UPHWIOZSXCZKNQ-UHFFFAOYSA-N CCCCCCC(CCCCCCCCCCC(NCCc1c[nH]c(cc2)c1cc2O)=O)O Chemical compound CCCCCCC(CCCCCCCCCCC(NCCc1c[nH]c(cc2)c1cc2O)=O)O UPHWIOZSXCZKNQ-UHFFFAOYSA-N 0.000 description 1
- SUNKILWHFLSCMU-UHFFFAOYSA-N CCCCCCCCCCCCCCCCNC(NCCc1c[nH]c(cc2)c1cc2O)=O Chemical compound CCCCCCCCCCCCCCCCNC(NCCc1c[nH]c(cc2)c1cc2O)=O SUNKILWHFLSCMU-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- QJDNHGXNNRLIGA-DOFZRALJSA-N N-arachidonoylserotonin Chemical compound C1=C(O)C=C2C(CCNC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC)=CNC2=C1 QJDNHGXNNRLIGA-DOFZRALJSA-N 0.000 description 1
- 208000024571 Pick disease Diseases 0.000 description 1
- 241000231366 Scorodocarpus Species 0.000 description 1
- 240000004482 Withania somnifera Species 0.000 description 1
- 235000001978 Withania somnifera Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- CKWKRGFFGOLULS-UHFFFAOYSA-N n-(2-ethylhexyl)-1h-indole-3-carboxamide Chemical compound C1=CC=C2C(C(=O)NCC(CC)CCCC)=CNC2=C1 CKWKRGFFGOLULS-UHFFFAOYSA-N 0.000 description 1
- FXPWUZWXAJDLDW-UHFFFAOYSA-N n-(3-ethyl-2-morpholin-4-ylpentyl)-3-(1h-indol-3-yl)propanamide Chemical compound C=1NC2=CC=CC=C2C=1CCC(=O)NCC(C(CC)CC)N1CCOCC1 FXPWUZWXAJDLDW-UHFFFAOYSA-N 0.000 description 1
- OHEKPPAXMOUGNE-ZDUSSCGKSA-N n-[(2s)-heptan-2-yl]-2-(6-methoxy-1-benzofuran-2-yl)acetamide Chemical compound C1=C(OC)C=C2OC(CC(=O)N[C@@H](C)CCCCC)=CC2=C1 OHEKPPAXMOUGNE-ZDUSSCGKSA-N 0.000 description 1
- CSNFRFGPKZFEMU-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-2-ethylhexanamide Chemical compound C1=C(Cl)C=C2C(CCNC(=O)C(CC)CCCC)=CNC2=C1 CSNFRFGPKZFEMU-UHFFFAOYSA-N 0.000 description 1
- SHOJKOAMMLTIDM-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-2-propylpentanamide Chemical compound C1=C(Cl)C=C2C(CCNC(=O)C(CCC)CCC)=CNC2=C1 SHOJKOAMMLTIDM-UHFFFAOYSA-N 0.000 description 1
- GPASTFKKYJALFN-UHFFFAOYSA-N n-[2-(5-methyl-1h-indol-3-yl)ethyl]-2-propylpentanamide Chemical compound C1=C(C)C=C2C(CCNC(=O)C(CCC)CCC)=CNC2=C1 GPASTFKKYJALFN-UHFFFAOYSA-N 0.000 description 1
- XFOIOLGFEYYALI-UHFFFAOYSA-N n-[2-(6-methoxy-1h-indol-3-yl)ethyl]-2-propylpentanamide Chemical compound COC1=CC=C2C(CCNC(=O)C(CCC)CCC)=CNC2=C1 XFOIOLGFEYYALI-UHFFFAOYSA-N 0.000 description 1
- LSYHNNWQFGUGIA-UHFFFAOYSA-N n-[2-(6-methoxy-1h-indol-3-yl)ethyl]dodecanamide Chemical compound COC1=CC=C2C(CCNC(=O)CCCCCCCCCCC)=CNC2=C1 LSYHNNWQFGUGIA-UHFFFAOYSA-N 0.000 description 1
- OUVFBIAMWCZKPP-UHFFFAOYSA-N n-dodecyl-2-(1h-indol-3-yl)-2-oxoacetamide Chemical compound C1=CC=C2C(C(=O)C(=O)NCCCCCCCCCCCC)=CNC2=C1 OUVFBIAMWCZKPP-UHFFFAOYSA-N 0.000 description 1
- SOKAVOBKMDJLCR-UHFFFAOYSA-N n-heptan-2-yl-3-(1h-indol-3-yl)propanamide Chemical compound C1=CC=C2C(CCC(=O)NC(C)CCCCC)=CNC2=C1 SOKAVOBKMDJLCR-UHFFFAOYSA-N 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- RKIDPTUGNXTOMU-UHFFFAOYSA-N thionyl iodide Chemical compound IS(I)=O RKIDPTUGNXTOMU-UHFFFAOYSA-N 0.000 description 1
- NIDHFQDUBOVBKZ-NSCUHMNNSA-N trans-hex-4-enoic acid Chemical compound C\C=C\CCC(O)=O NIDHFQDUBOVBKZ-NSCUHMNNSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12494908P | 2008-04-21 | 2008-04-21 | |
| US61/124,949 | 2008-04-21 | ||
| US12520508P | 2008-04-23 | 2008-04-23 | |
| US61/125,205 | 2008-04-23 | ||
| US12790008P | 2008-05-16 | 2008-05-16 | |
| US61/127,900 | 2008-05-16 | ||
| PCT/US2009/041321 WO2009132051A1 (en) | 2008-04-21 | 2009-04-21 | Compounds, compositions and methods for making the same |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012082834A Division JP2012126753A (ja) | 2008-04-21 | 2012-03-30 | 化合物、組成物およびそれらを作製する方法 |
| JP2014161026A Division JP2014208706A (ja) | 2008-04-21 | 2014-08-07 | 化合物、組成物およびそれらを作製する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011518196A JP2011518196A (ja) | 2011-06-23 |
| JP2011518196A5 true JP2011518196A5 (enExample) | 2013-05-16 |
| JP5607025B2 JP5607025B2 (ja) | 2014-10-15 |
Family
ID=41201651
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011505265A Expired - Fee Related JP5607025B2 (ja) | 2008-04-21 | 2009-04-21 | 化合物、組成物およびそれらを作製する方法 |
| JP2012082834A Withdrawn JP2012126753A (ja) | 2008-04-21 | 2012-03-30 | 化合物、組成物およびそれらを作製する方法 |
| JP2014161026A Pending JP2014208706A (ja) | 2008-04-21 | 2014-08-07 | 化合物、組成物およびそれらを作製する方法 |
| JP2016086766A Expired - Fee Related JP6383377B2 (ja) | 2008-04-21 | 2016-04-25 | 化合物、組成物およびそれらを作製する方法 |
| JP2016086767A Pending JP2016135809A (ja) | 2008-04-21 | 2016-04-25 | 化合物、組成物およびそれらを作製する方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012082834A Withdrawn JP2012126753A (ja) | 2008-04-21 | 2012-03-30 | 化合物、組成物およびそれらを作製する方法 |
| JP2014161026A Pending JP2014208706A (ja) | 2008-04-21 | 2014-08-07 | 化合物、組成物およびそれらを作製する方法 |
| JP2016086766A Expired - Fee Related JP6383377B2 (ja) | 2008-04-21 | 2016-04-25 | 化合物、組成物およびそれらを作製する方法 |
| JP2016086767A Pending JP2016135809A (ja) | 2008-04-21 | 2016-04-25 | 化合物、組成物およびそれらを作製する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9486441B2 (enExample) |
| EP (1) | EP2282735B1 (enExample) |
| JP (5) | JP5607025B2 (enExample) |
| CN (1) | CN102014897B (enExample) |
| AU (3) | AU2009239430B2 (enExample) |
| CA (1) | CA2758424C (enExample) |
| WO (1) | WO2009132051A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7565145B2 (en) | 2002-10-18 | 2009-07-21 | Kineto Wireless, Inc. | Handover messaging in an unlicensed mobile access telecommunications system |
| US7940746B2 (en) | 2004-08-24 | 2011-05-10 | Comcast Cable Holdings, Llc | Method and system for locating a voice over internet protocol (VoIP) device connected to a network |
| US20090175973A1 (en) * | 2007-09-05 | 2009-07-09 | Nina Vikhrieva | Coffee cherry compositions and methods for their use in the treatment of diabetes and diabetes related disorders |
| EP2282735B1 (en) | 2008-04-21 | 2019-01-16 | Signum Biosciences, Inc. | Pp2a modulators for treating alzheimer, parkinson, diabetes |
| DE102008025893B4 (de) * | 2008-05-26 | 2014-09-18 | Technische Universität Dresden | Verfahren zur Herstellung von Fettsäureamiden mit gesättigten, ungesättigten oder Hydroxy-Fettsäuren |
| FR2942625B1 (fr) * | 2009-03-02 | 2013-11-22 | Centre Nat Rech Scient | Derives indoliques pour le traitement de maladies neurodegeneratives |
| US9073851B2 (en) | 2011-10-28 | 2015-07-07 | Board Of Regents, The University Of Texas System | Compositions and methods for treating cancer |
| CN103086948A (zh) * | 2011-11-02 | 2013-05-08 | 上海朴颐化学科技有限公司 | (s,s,s)-2-氮杂双环[3,3,0]辛烷-3-羧酸的制备方法 |
| CA2877167A1 (en) | 2012-06-29 | 2014-01-03 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes |
| US20170224757A1 (en) | 2014-07-22 | 2017-08-10 | Signum Nutralogix, Inc. | Natural extracts for modulating pp2a methylation, and providing antioxidant and anti inflammatory activity |
| MX395174B (es) * | 2014-10-15 | 2025-03-21 | Signum Biosciences Inc | Composiciones de triptamina y metodos de uso. |
| US20160201009A1 (en) * | 2015-01-10 | 2016-07-14 | Aurelio Lopez | Integrated oil extraction apparatus |
| KR101874594B1 (ko) * | 2016-12-07 | 2018-07-05 | 한국한의학연구원 | 아떼모야 잎 추출물 또는 이의 분획물을 포함하는 인지기능 장애의 예방 또는 치료용 조성물 |
| WO2020092930A1 (en) * | 2018-11-02 | 2020-05-07 | Rutgers, The State University Of New Jersey | Synergistic composition having neuroprotective properties and methods of use thereof |
| EP4003363A4 (en) * | 2019-07-25 | 2023-08-16 | North Carolina State University | CROSS-LINKING COMPOUNDS AND METHODS OF USE |
| JP2021028325A (ja) * | 2019-08-09 | 2021-02-25 | 株式会社ＡＣｒｕｘ | 中枢機能改善剤および中枢機能改善用飲食品 |
| EP4334285A4 (en) * | 2021-05-05 | 2025-07-30 | Kare Chemical Tech Inc | CATALYTIC TRYPTAMINE PROCESSES AND PRECURSORS |
| WO2023019368A1 (en) * | 2021-08-20 | 2023-02-23 | Mindset Pharma Inc. | 3-cycloamino-indole compounds as serotonergic agents useful for the treatment of disorders related thereto |
Family Cites Families (191)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2852520A (en) | 1957-01-08 | 1958-09-16 | Searle & Co | Trialkoxybenzoyloxyalkyl derivatives related to norharman |
| DE2856856A1 (de) * | 1978-01-09 | 1979-07-12 | Sandoz Ag | Fettsaeure-amid-und-hydracid derivate, ihre herstellung und ihre verwendung als pharmazeutika |
| US4448785A (en) * | 1978-01-09 | 1984-05-15 | Sandoz, Inc. | N-Unsaturated fatty acid amides of tryptophan ester homologues and anti-cholesteric use thereof |
| US4185118A (en) | 1978-01-09 | 1980-01-22 | Sandoz, Inc. | Benzocycloalkylamides |
| US4194002A (en) | 1978-03-29 | 1980-03-18 | Sandoz, Inc. | Cholesterol ester-reducing amides of hexahydroindolinols |
| US4229463A (en) | 1978-02-27 | 1980-10-21 | Sandoz, Inc. | Unsaturated fatty acid hydrazides |
| US4201785A (en) | 1978-02-27 | 1980-05-06 | Sandoz Inc. | Cyclopropanyl-bearing hydrazides |
| US4248893A (en) | 1978-12-30 | 1981-02-03 | Sandoz, Inc. | Arterial wall cholesterol ester reducing cyclopropanyl-bearing amides |
| DE3105850A1 (de) | 1981-02-18 | 1982-08-19 | Horst, Hans Jörg, Priv.Doz.Dr., 2057 Reinbek | Mittel zum behandeln von tumoren |
| CA1280414C (en) | 1985-03-15 | 1991-02-19 | Saichi Matsumoto | Isoprenoidamine derivatives and antiulcer agents |
| US4709094A (en) | 1986-07-10 | 1987-11-24 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Sigma brain receptor ligands and their use |
| US4906779A (en) | 1986-07-10 | 1990-03-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists |
| US5093525A (en) | 1986-07-10 | 1992-03-03 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists |
| US5190976A (en) | 1986-07-10 | 1993-03-02 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And University Of Oregon | N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists |
| JPH0752542Y2 (ja) | 1988-02-26 | 1995-11-29 | 東芝設備機器株式会社 | 冷却器 |
| US4933324A (en) | 1988-02-26 | 1990-06-12 | Shashoua Victor E | Fatty acid-neuroactive drug conjugate as a prodrug |
| US5284876A (en) | 1988-02-26 | 1994-02-08 | Neuromedica, Inc. | Method of treating tardive dyskinesia using dopaminergic agents of prodrugs of therapeutic agents |
| US4939174A (en) | 1988-02-26 | 1990-07-03 | Shashoua Victor E | Appetite suppression with dopamine-fatty acid conjugates |
| US5994392A (en) | 1988-02-26 | 1999-11-30 | Neuromedica, Inc. | Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid |
| US6107499A (en) | 1988-02-26 | 2000-08-22 | Neuromedica, Inc. | Dopamine analog amide |
| US4935422A (en) | 1988-12-15 | 1990-06-19 | E. I. Du Pont De Nemours And Company | Acyloxypropanolamines |
| US5175183A (en) | 1989-02-01 | 1992-12-29 | Abbott Laboratories | Lipoxygenase inhibiting compounds |
| IE68593B1 (en) | 1989-12-06 | 1996-06-26 | Sanofi Sa | Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them |
| JPH0625276Y2 (ja) | 1989-12-29 | 1994-07-06 | 株式会社ワコール | 硬質線状体の押込み手作業用プロテクタ |
| IT1243846B (it) | 1990-10-17 | 1994-06-28 | Pulitzer Italiana | Derivato della melatonina ad attivita' terapeutica in dermatologia. |
| EP0590009B1 (en) | 1991-06-19 | 1998-03-18 | PHARMACIA & UPJOHN COMPANY | Dialkyl (dialkoxyphosphinyl)methyl phosphates as anti-inflammatory agents |
| GB9218541D0 (en) | 1991-09-30 | 1992-10-14 | Ici Plc | Fungicides |
| FR2706456B1 (fr) | 1993-06-18 | 1996-06-28 | Rhone Poulenc Agrochimie | Dérivés optiquement actifs de 2-imidazoline-5-ones et 2-imidazoline-5-thiones fongicides. |
| US5322858A (en) | 1992-02-14 | 1994-06-21 | Jacobus Pharmaceutical Co. Inc. | N,N'-substituted imidodicarbonimidic diamides derived from hydroxylamines |
| JPH0625276A (ja) | 1992-05-13 | 1994-02-01 | Tanabe Seiyaku Co Ltd | アシルアミノ糖誘導体及びその製法 |
| US5585358A (en) | 1993-07-06 | 1996-12-17 | Yissum Research Development Corporation Of The Hebrew University Of Jerusalem | Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents |
| EP0634402A1 (en) | 1993-07-14 | 1995-01-18 | Takeda Chemical Industries, Ltd. | Isochinolinone derivatives, their production and use |
| JP3268073B2 (ja) | 1993-08-17 | 2002-03-25 | 三菱製紙株式会社 | 可逆性感熱記録材料 |
| US6869957B1 (en) | 1993-11-17 | 2005-03-22 | Eli Lilly And Company | Non-peptide tachykinin receptor antagonists |
| US6403577B1 (en) | 1993-11-17 | 2002-06-11 | Eli Lilly And Company | Hexamethyleneiminyl tachykinin receptor antagonists |
| ATE346595T1 (de) * | 1994-02-08 | 2006-12-15 | Nps Pharma Inc | An einer neuen stelle von rezeptorabhängigen kalziumkanälen wirkende verbindungen zur behandlung von neurologischen erkrankungen |
| DE69519963T2 (de) * | 1994-07-23 | 2001-06-21 | Societe Des Produits Nestle S.A., Vevey | Antioxidantzusammensetzung und Verfahren zu ihrer Herstellung |
| FR2724384B1 (fr) | 1994-09-14 | 1999-04-16 | Cemaf | Nouveaux derives de la 3,4-dihydro beta-carboline agonistes de la melatonine, leur procede de preparation et leur utilisation a titre de medicament |
| JP3795093B2 (ja) | 1994-11-25 | 2006-07-12 | キッセイ薬品工業株式会社 | １−ヒドロキシインドール誘導体 |
| JPH08157816A (ja) | 1994-12-02 | 1996-06-18 | Oriza Yuka Kk | 天然抗酸化剤およびその製造方法 |
| GB9426102D0 (en) | 1994-12-23 | 1995-02-22 | Merck Sharp & Dohme | Pharmacuetical compositions |
| HUP9702388A3 (en) | 1995-01-27 | 1999-01-28 | Novo Nordisk As | Compounds with growth hormone releasing properties and pharmaceuticals contg. them |
| FR2734814B1 (fr) | 1995-05-31 | 1997-07-04 | Adir | Nouveaux composes alkoxy-aryles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| GB9513972D0 (en) | 1995-07-08 | 1995-09-06 | Merck Sharp & Dohme | Pharmaceutical compositions |
| CA2203424A1 (en) | 1995-08-21 | 1997-02-27 | Eli Lilly And Company | 2-acylaminopropanamines as growth hormone secretagogues |
| US5821261A (en) | 1995-12-08 | 1998-10-13 | Merck & Co., Inc. | Substituted saturated aza heterocycles as inhibitors of nitric oxide synthase |
| US5849764A (en) * | 1995-12-14 | 1998-12-15 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| JPH09301954A (ja) | 1996-05-14 | 1997-11-25 | Kumiai Chem Ind Co Ltd | Ｎ−（縮合ヘテロアリールアルキル）アルカン酸アミド誘導体及び農園芸用殺菌剤 |
| US5795877A (en) | 1996-12-31 | 1998-08-18 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
| US5902817A (en) | 1997-04-09 | 1999-05-11 | Guilford Pharmaceuticals Inc. | Certain sulfoxide and sulfone derivatives |
| US5977090A (en) | 1996-09-27 | 1999-11-02 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors |
| US5824662A (en) | 1996-09-27 | 1998-10-20 | Guilford Pharmaceuticals Inc. | Treatment of global and focal ischemia using naaladase inhibitors |
| US6025344A (en) | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Certain dioic acid derivatives useful as NAALADase inhibitors |
| US6054444A (en) | 1997-04-24 | 2000-04-25 | Guilford Pharmaceuticals Inc. | Phosphonic acid derivatives |
| US6017903A (en) | 1996-09-27 | 2000-01-25 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors |
| US5863536A (en) | 1996-12-31 | 1999-01-26 | Guilford Pharmaceuticals Inc. | Phosphoramidate derivatives |
| US6071965A (en) | 1996-06-17 | 2000-06-06 | Guilford Pharmaceuticals Inc. | Phosphinic alkanoic acid derivatives |
| US6046180A (en) | 1996-06-17 | 2000-04-04 | Guilford Pharmaceuticals Inc. | NAALADase inhibitors |
| US5700821A (en) | 1996-07-30 | 1997-12-23 | University Of Pittsburgh | Phosphatase inhibitors and methods of use thereof |
| AU6824396A (en) | 1996-08-09 | 1998-03-06 | Sederma Sa | Melatonin derivatives and their use in cosmetic or dermopharmaceutical compositions |
| JPH1077229A (ja) | 1996-09-03 | 1998-03-24 | Sagami Chem Res Center | 自発運動抑制剤 |
| JPH1077267A (ja) | 1996-09-03 | 1998-03-24 | Sagami Chem Res Center | ５−メトキシトリプタミン誘導体 |
| US5962521A (en) | 1997-04-04 | 1999-10-05 | Guilford Pharmaceuticals Inc. | Hydroxamic acid derivatives |
| GB9620777D0 (en) | 1996-10-07 | 1996-11-20 | Merck Sharp & Dohme | Therapeutic use |
| AT2009U1 (de) | 1997-01-24 | 1998-03-25 | Trodat Werke Walter Just Gmbh | Einrichtung zur ablage von handstempeln und anderen büroutensilien |
| RU2141483C1 (ru) | 1997-07-04 | 1999-11-20 | Небольсин Владимир Евгеньевич | Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция |
| CA2295697A1 (en) | 1997-07-10 | 1999-01-21 | Jason Scott Sawyer | Inhibitors of neutrophil mediated oxidant production |
| CN1067527C (zh) | 1997-07-13 | 2001-06-27 | 赵宁斌 | 柿叶茶的制备方法 |
| AP9801302A0 (en) | 1997-07-23 | 2000-01-23 | Pfizer | Indole compounds as anti-inflammatory/analgesic agents.. |
| US7041702B1 (en) | 1997-10-21 | 2006-05-09 | Scion Pharmaceuticals, Inc. | Pharmaceutically active compounds and methods of use |
| HU227568B1 (en) | 1997-12-24 | 2011-08-29 | Sanofi Aventis Deutschland | Indole derivatives, as inhibitors os factor xa |
| GB9804343D0 (en) | 1998-02-27 | 1998-04-22 | Univ Cardiff | Chemical compounds |
| WO1999054442A1 (en) | 1998-04-17 | 1999-10-28 | Emory University | Protein phosphatase methylesterase dna |
| FR2778671B1 (fr) | 1998-05-14 | 2002-07-05 | Rhone Poulenc Agrochimie | Nouveau procede de preparation d'intermediaires de synthese |
| GB9812083D0 (en) | 1998-06-05 | 1998-08-05 | Ici Plc | Removal of water |
| WO2000012045A2 (en) | 1998-08-26 | 2000-03-09 | St. Elizabeth's Medical Center Of Boston, Inc. | Method for treating neurodegenerative disorders |
| DE19842416A1 (de) * | 1998-09-16 | 2000-04-13 | Max Planck Gesellschaft | Sekundäre Amine zur Prävention und Therapie von Erkrankungen, die durch Oxidationsprozesse verursacht oder verstärkt werden |
| IL145771A0 (en) | 1999-04-09 | 2002-07-25 | Basf Ag | Low-molecular inhibitors of complement proteases |
| US6503949B1 (en) | 1999-05-17 | 2003-01-07 | Noro Nordisk A/S | Glucagon antagonists/inverse agonists |
| WO2001021606A1 (en) | 1999-09-21 | 2001-03-29 | Qinetiq Limited | Liquid crystal compounds |
| AU7832000A (en) | 1999-09-23 | 2001-04-24 | Washington University | Compounds directed against pilus biogenesis and activity in pathogenic bacteria;methods and compositions for synthesis thereof |
| US20030036070A1 (en) | 1999-10-21 | 2003-02-20 | Shukti Chakravarti | Gene expression profiling of inflammatory bowel disease |
| FR2802206B1 (fr) | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| US6372752B1 (en) | 2000-02-07 | 2002-04-16 | Genzyme Corporation | Inha inhibitors and methods of use thereof |
| US6653304B2 (en) | 2000-02-11 | 2003-11-25 | Bristol-Myers Squibb Co. | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
| JP2001247539A (ja) | 2000-03-03 | 2001-09-11 | Hunan Research Inst Of Chemical Industry | 殺生物性のアルキル置換された（ヘテロ）アリール‐ケトキシム‐ｏ‐エーテルおよびその製造方法 |
| AU779041B2 (en) | 2000-05-02 | 2005-01-06 | Meiji Seika Kaisha Ltd. | Novel indole derivatives exhibiting chymase-inhibitory activities and process for preparation thereof |
| US20020034524A1 (en) | 2000-06-19 | 2002-03-21 | Poret Jacques Louis | Cosmetic compositions containing keratinization modulators and methods for improving keratinous surfaces |
| US6562807B2 (en) | 2000-06-23 | 2003-05-13 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| CA2321348A1 (en) | 2000-09-27 | 2002-03-27 | Blaise Magloire N'zemba | Aromatic derivatives with hiv integrase inhibitory properties |
| US20040053963A1 (en) | 2000-12-11 | 2004-03-18 | Dashyant Dhanak | Urotensin-II receptor antagonists |
| JP2002193923A (ja) | 2000-12-26 | 2002-07-10 | Taisho Pharmaceut Co Ltd | アミノ安息香酸誘導体 |
| WO2003080556A1 (en) | 2001-01-19 | 2003-10-02 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. | Amine derivative with potassium channel regulatory function, its preparation and use |
| JP2004524295A (ja) | 2001-01-26 | 2004-08-12 | スミスクライン・ビーチャム・コーポレイション | ウロテンシン−ｉｉ受容体アンタゴニスト |
| US7173027B2 (en) | 2001-01-29 | 2007-02-06 | University Of Connecticut | Receptor selective cannabimimetic aminoalkylindoles |
| US7820144B2 (en) | 2001-01-29 | 2010-10-26 | University Of Connecticut | Receptor selective cannabimimetic aminoalkylindoles |
| AUPR392301A0 (en) | 2001-03-23 | 2001-04-26 | University Of Newcastle Research Associates Limited, The | Protein phosphatase inhibitors |
| US20040138224A1 (en) | 2002-03-28 | 2004-07-15 | Dashyant Dhanak | Pyrrolidine sulfonamides |
| WO2002079155A1 (en) | 2001-03-29 | 2002-10-10 | Smithkline Beecham Corporation | Pyrrolidine sulfonamides |
| EP1392639B1 (en) | 2001-05-03 | 2008-09-17 | Galileo Laboratories, Inc. | Pyruvate derivatives |
| US6608196B2 (en) | 2001-05-03 | 2003-08-19 | Galileo Pharmaceuticals, Inc. | Process for solid supported synthesis of pyruvate-derived compounds |
| SE0101978D0 (sv) | 2001-06-01 | 2001-06-01 | Astrazeneca Ab | New compounds |
| WO2003008632A1 (en) | 2001-07-16 | 2003-01-30 | Hoegestaett Edward | Fatty acid conjugation as a method for screening of potentially bioactive substances |
| US7262268B2 (en) * | 2001-08-06 | 2007-08-28 | Cubist Pharmaceuticals, Inc. | Lipopeptide stereoisomers, methods for preparing same, and useful intermediates |
| AU2002324666B2 (en) | 2001-08-10 | 2007-10-11 | The Rockefeller University | Compostions and methods for modulation of DARPP-32 phosphorylation |
| AU2002336532C1 (en) | 2001-09-14 | 2008-10-16 | Amgen, Inc | Linked biaryl compounds |
| US20030215456A1 (en) | 2001-10-02 | 2003-11-20 | Sui-Long Yao | Method of treating cancer |
| AU2002342859B2 (en) | 2001-10-30 | 2007-07-26 | Merck Serono Sa | Oxindole hydrazide modulators of protein tyrosine phosphatases (PTPS) |
| JP4156825B2 (ja) | 2001-11-01 | 2008-09-24 | 株式会社ロッテ | 抗鬱・抗ストレス剤及びそれを含有する組成物 |
| AU2002363177B2 (en) | 2001-11-01 | 2008-09-18 | Janssen Pharmaceutica N.V. | Aminobenzamide derivatives as glycogen synthase kinase 3Beta inhibitors |
| CN1205175C (zh) | 2001-11-02 | 2005-06-08 | 中国人民解放军军事医学科学院毒物药物研究所 | 胺衍生物在制备具有抗肺动脉高压作用的药物中用途 |
| US20030171411A1 (en) | 2001-12-21 | 2003-09-11 | Kodra Janos Tibor | Amide derivatives as therapeutic agents |
| US7794965B2 (en) | 2002-03-13 | 2010-09-14 | Signum Biosciences, Inc. | Method of identifying modulators of PP2A methylase |
| US20040138238A1 (en) | 2002-08-08 | 2004-07-15 | Dhanoa Dale S. | Substituted aminopyrimidine compounds as neurokinin antagonists |
| WO2004031177A1 (ja) | 2002-09-30 | 2004-04-15 | Banyu Pharmaceutical Co., Ltd. | ２−アミノベンズイミダゾール誘導体 |
| DE10253426B4 (de) | 2002-11-15 | 2005-09-22 | Elbion Ag | Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung |
| DE10300099A1 (de) | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Indol-Phenylsulfonamid-Derivate |
| WO2004063147A1 (en) | 2003-01-10 | 2004-07-29 | Novo Nordisk A/S | Salts and solvates of glucagon antagonists |
| JP5208411B2 (ja) | 2003-02-06 | 2013-06-12 | ドムペ・ファ．ル．マ・ソチエタ・ペル・アツィオーニ | ２−アリール−酢酸、その誘導体、及びそれらを含有する医薬組成物 |
| JP4421832B2 (ja) | 2003-03-27 | 2010-02-24 | 株式会社常磐植物化学研究所 | 記憶促進剤 |
| AU2004236247B2 (en) | 2003-04-30 | 2008-11-06 | The Institutes For Pharmaceutical Discovery, Llc | Substituted amino carboxylic acids as inhibitors of protein tyrosine phosphatase-1 B |
| WO2005001041A2 (en) | 2003-05-28 | 2005-01-06 | Paul Anziano | Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase |
| NZ545747A (en) | 2003-08-06 | 2010-06-25 | Senomyx Inc | T1R hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds |
| WO2005014532A1 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
| WO2005019168A2 (en) | 2003-08-20 | 2005-03-03 | Pfizer Products Inc. | Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors |
| US7282593B2 (en) | 2003-09-11 | 2007-10-16 | Board Of Trustees Of Michigan State University | Withanamide and withanolide compositions and method of use thereof |
| FR2860793A1 (fr) | 2003-10-14 | 2005-04-15 | Entomed | Composes derives de norcantharidine, leurs procedes de preparation, les compositions les contenant et leurs utilisations |
| DE602004011985T2 (de) | 2003-11-25 | 2009-03-05 | Eli Lilly And Co., Indianapolis | Modulatoren des peroxisomproliferatoraktivierten rezeptors |
| CA2548281C (en) | 2003-12-09 | 2013-11-12 | Medcrystalforms, Llc | Method of preparation of mixed phase co-crystals with active agents |
| WO2005071101A1 (en) | 2004-01-23 | 2005-08-04 | University Hospital Of Basel | Treatment of hepatitis c infection by increasing stat1 methylation |
| EP1711495A2 (en) | 2004-01-23 | 2006-10-18 | Amgen Inc. | Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer |
| US8053462B2 (en) | 2004-03-08 | 2011-11-08 | Masanori Somei | Indole derivative and application thereof |
| EP1744751A4 (en) | 2004-03-18 | 2010-03-10 | Brigham & Womens Hospital | METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES |
| AU2006230674A1 (en) | 2004-03-18 | 2006-11-16 | The Brigham And Women's Hospital, Inc. | Methods for the Treatment of Synucleinopathies |
| CA2561801A1 (en) | 2004-04-02 | 2005-10-20 | Elixir Pharmaceuticals, Inc. | Sulfonamides and uses thereof |
| CN101031289A (zh) | 2004-04-26 | 2007-09-05 | 范德比尔特大学 | 作为具有降低胃肠毒性的治疗剂的吲哚乙酸和茚乙酸衍生物 |
| US20050250819A1 (en) | 2004-05-07 | 2005-11-10 | Xiaobing Li | Inhibitors of bacterial type III protein secretion systems |
| FR2872704B1 (fr) | 2004-07-12 | 2007-11-02 | Laurent Schwartz | Pluritherapie contre le cancer |
| US20060045953A1 (en) | 2004-08-06 | 2006-03-02 | Catherine Tachdjian | Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers |
| EP1790640A4 (en) | 2004-09-09 | 2009-07-29 | Chugai Pharmaceutical Co Ltd | NEW IMIDAZOLIDINE DERIVATIVE AND APPLICATION THEREOF |
| JP3964417B2 (ja) | 2004-09-27 | 2007-08-22 | 国立大学法人金沢大学 | インドール誘導体を有効成分とするα２受容体遮断剤及び血管拡張剤 |
| CA2585934C (en) | 2004-10-29 | 2013-09-10 | Abbott Laboratories | Novel pyrazolopyridine urea kinase inhibitors |
| ES2321858T3 (es) | 2004-11-11 | 2009-06-12 | Ferrer Internacional, S.A. | Compuestos de imidazo(1,2-a)piridina, composiciones, usos y metodos relacionados. |
| US20060160109A1 (en) | 2004-11-22 | 2006-07-20 | Odyssey Thera, Inc. | Harnessing network biology to improve drug discovery |
| US20070212677A1 (en) | 2004-11-22 | 2007-09-13 | Odyssey Thera, Inc. | Identifying off-target effects and hidden phenotypes of drugs in human cells |
| CA2587664A1 (en) | 2004-12-21 | 2006-06-29 | Devgen N.V. | Compounds with kv4 ion channel activity |
| FR2879601B1 (fr) | 2004-12-22 | 2007-01-19 | Galderma Res & Dev | Nouveaux composes derives d'acide phenyl-boronique et leur procede de preparation |
| EP1676842A1 (en) | 2004-12-30 | 2006-07-05 | Laboratorios Del Dr. Esteve, S.A. | Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicaments |
| US20070161644A1 (en) | 2005-01-25 | 2007-07-12 | Stockwell Brent R | Erastin analogs and uses thereof |
| AU2006209245A1 (en) | 2005-01-28 | 2006-08-03 | Irm Llc | Phenyl-substituted pyrrolidones |
| US8221804B2 (en) * | 2005-02-03 | 2012-07-17 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| EP1853590A1 (en) | 2005-03-03 | 2007-11-14 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
| WO2006101456A1 (en) | 2005-03-21 | 2006-09-28 | S*Bio Pte Ltd | Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors |
| JP2008534593A (ja) | 2005-03-30 | 2008-08-28 | メルク エンド カムパニー インコーポレーテッド | グルカゴン受容体アンタゴニスト化合物、そのような化合物を含む組成物、及びその使用方法 |
| CN1304396C (zh) | 2005-04-08 | 2007-03-14 | 中山大学 | 斑蝥素衍生物及其制备方法 |
| TW200738677A (en) | 2005-06-27 | 2007-10-16 | Elbion Ag | Nitro-substituted hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them |
| WO2007008514A2 (en) | 2005-07-07 | 2007-01-18 | Georgetown University | Inhibitors of glycogen synthase kinase 3 |
| WO2007015866A2 (en) | 2005-07-20 | 2007-02-08 | Kalypsys, Inc. | Inhibitors of p38 kinase and methods of treating inflammatory disorders |
| JP2009504712A (ja) | 2005-08-17 | 2009-02-05 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | カリウムチャンネル阻害化合物の使用方法 |
| EP1931632A4 (en) | 2005-08-18 | 2011-05-11 | Microbia Inc | USEFUL INDOOR CONNECTIONS |
| AU2006302371A1 (en) | 2005-10-06 | 2007-04-19 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding cassette transporters |
| US20080021198A1 (en) | 2005-10-12 | 2008-01-24 | Yigong Shi | Modulators of protein phosphatase 2A and PP2A methyl esterase |
| US7902251B2 (en) | 2005-10-19 | 2011-03-08 | Allergan, Inc. | Method for treating pain |
| US20070105940A1 (en) | 2005-10-19 | 2007-05-10 | Allergan, Inc. | Method for treating pain |
| US20070259945A1 (en) | 2005-10-19 | 2007-11-08 | Allergan, Inc. | Method for treating pain |
| JP4993900B2 (ja) | 2005-11-28 | 2012-08-08 | 国立大学法人 東京医科歯科大学 | 記憶障害抑制剤 |
| CN1974545B (zh) * | 2005-11-29 | 2010-05-26 | 上海第二医科大学 | 长链脂肪酰胺类化合物及其应用 |
| DE102005061428A1 (de) | 2005-12-22 | 2007-08-16 | Grünenthal GmbH | Substituierte Cyclohexylmethyl-Derivate |
| AR059826A1 (es) | 2006-03-13 | 2008-04-30 | Univ California | Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble |
| GB0611417D0 (en) | 2006-06-09 | 2006-07-19 | Leuven K U Res & Dev | Treatment of cndaria intoxication |
| CA2657093A1 (en) | 2006-07-07 | 2008-01-10 | Steven P. Govek | Bicyclic heteroaryl inhibitors of pde4 |
| WO2008007123A2 (en) | 2006-07-14 | 2008-01-17 | Astex Therapeutics Limited | Pharmaceutical compounds |
| AU2007281747B2 (en) | 2006-08-07 | 2013-11-07 | Ironwood Pharmaceuticals, Inc. | Indole compounds |
| RU2446157C2 (ru) | 2006-09-13 | 2012-03-27 | Санофи-Авентис | Изосериновые производные для применения в качестве ингибиторов фактора свертывания крови ixa |
| EP2068869A4 (en) | 2006-10-06 | 2011-05-25 | Abbott Lab | NEW IMIDAZOTHIAZOLE AND IMIDAZOXAZOLE |
| US7960569B2 (en) | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| EP2076513A1 (en) | 2006-10-20 | 2009-07-08 | Irm Llc | Compositions and methods for modulating c-kit and pdgfr receptors |
| GB0623258D0 (en) | 2006-11-22 | 2007-01-03 | Remynd Nv | Thiadiazole derivatives for the treatment of neuro-degenerative diseases |
| JP4771975B2 (ja) | 2007-02-27 | 2011-09-14 | 三菱製紙株式会社 | 可逆性感熱記録材料 |
| US20100184803A1 (en) | 2007-03-09 | 2010-07-22 | Link Medicine Corporation | Treatment of Lysosomal Storage Diseases |
| EA200970841A1 (ru) | 2007-03-09 | 2010-04-30 | ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Фармацевтическое применение замещенных амидов |
| DE102007012284A1 (de) | 2007-03-16 | 2008-09-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| WO2008141013A1 (en) | 2007-05-08 | 2008-11-20 | Allergan, Inc. | S1p3 receptor inhibitors for treating pain |
| EP1992621A1 (en) | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases |
| EP1992624A1 (en) | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Heteroarylamide pyrimidone compounds |
| US20110236953A1 (en) | 2007-08-03 | 2011-09-29 | Beth Israel Deaconness Medical Center | EMBRYONIC CEREBROSPINAL FLUID (e-CSF), PROTEINS FROM e-CSF, AND RELATED METHODS AND COMPOSITIONS |
| EP2282735B1 (en) | 2008-04-21 | 2019-01-16 | Signum Biosciences, Inc. | Pp2a modulators for treating alzheimer, parkinson, diabetes |
| JP4842996B2 (ja) | 2008-06-09 | 2011-12-21 | 株式会社ロッテ | 抗鬱・抗ストレス組成物 |
| CN115941304B (zh) | 2022-11-29 | 2025-10-03 | 深圳云里物里科技股份有限公司 | 数据的加密方法、装置、终端设备和计算机可读存储介质 |
-
2009
- 2009-04-21 EP EP09734282.8A patent/EP2282735B1/en not_active Not-in-force
- 2009-04-21 WO PCT/US2009/041321 patent/WO2009132051A1/en not_active Ceased
- 2009-04-21 US US12/427,743 patent/US9486441B2/en not_active Expired - Fee Related
- 2009-04-21 CA CA2758424A patent/CA2758424C/en active Active
- 2009-04-21 JP JP2011505265A patent/JP5607025B2/ja not_active Expired - Fee Related
- 2009-04-21 AU AU2009239430A patent/AU2009239430B2/en not_active Ceased
- 2009-04-21 CN CN200980114132.4A patent/CN102014897B/zh not_active Expired - Fee Related
-
2012
- 2012-03-30 JP JP2012082834A patent/JP2012126753A/ja not_active Withdrawn
-
2014
- 2014-08-07 JP JP2014161026A patent/JP2014208706A/ja active Pending
-
2015
- 2015-04-22 AU AU2015202037A patent/AU2015202037A1/en not_active Abandoned
-
2016
- 2016-04-25 JP JP2016086766A patent/JP6383377B2/ja not_active Expired - Fee Related
- 2016-04-25 JP JP2016086767A patent/JP2016135809A/ja active Pending
- 2016-11-08 US US15/346,636 patent/US10583119B2/en not_active Expired - Fee Related
- 2016-12-15 AU AU2016273941A patent/AU2016273941B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011518196A5 (enExample) | ||
| KR101739994B1 (ko) | 프로판-１-술폰산 ｛３-［５-（４-클로로-페닐）-１Ｈ-피롤로［２，３-ｂ］피리딘-３-카르보닐］-２，４-디플루오로-페닐｝-아미드 조성물 및 그의 용도 | |
| US20190231766A1 (en) | Administration of ethyl 3-[(2-{[4-(hexyloxycarbonyl-aminoiminomethyl)phenyl-amino]methyl}-1-methyl-1h-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionate | |
| KR20150015021A (ko) | 브루톤 타이로신 키나아제 저해제의 결정 형태 | |
| JP2012126753A5 (enExample) | ||
| ES2610966T3 (es) | Formulaciones que comprenden 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol | |
| US20130316982A1 (en) | Novel crystalline forms | |
| ES2969901T3 (es) | Cocristal de ácido benzoico y compuesto de sulfonamida para el tratamiento de tumores | |
| CA3068609A1 (en) | Compositions and methods for treatment of cystic fibrosis | |
| KR101854879B1 (ko) | 염증성 질환의 치료에 사용하기 위한 n-아실에탄올아민에 특이적인 아미다제의 조절용 조성물 및 조절 방법 | |
| US20120059058A1 (en) | Dispersions of rasagiline citrate | |
| ES2776879T3 (es) | Una composición farmacéutica para dolor neuropático | |
| CA2671976A1 (en) | Methods of inducing terminal differentiation | |
| BRPI0918802A2 (pt) | uso de (s)-n-[[3-[3-fluoro-4-(4-tiomorfolinil)fenil]-2-oxo-5-oxazolidinil] metil] acetamida e composição farmacêutica | |
| CN112521367A (zh) | 作为葡糖神经酰胺合酶的抑制剂的无定型和结晶形式的Genz 112638半酒石酸盐 | |
| KR20180101521A (ko) | Btk 저해제를 포함하는 제형/조성물 | |
| Rangnekar et al. | Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis | |
| KR20180102150A (ko) | Btk 저해제를 포함하는 제형/조성물 | |
| CN101663026A (zh) | 氨基甲酸苯基烷基酯组合物 | |
| WO2016020919A1 (en) | Compositions comprising tricyclic compounds, and uses thereof | |
| CN102234265A (zh) | 兰索拉唑化合物 | |
| EA037149B1 (ru) | Биодоступные полиамины | |
| EP2998305B1 (en) | Pyrroloquinoline quinone lithium salt crystal and preparation method and application thereof | |
| JP7397487B2 (ja) | 感覚有毛細胞死を予防または処置するための化合物の結晶形態 | |
| TW200920348A (en) | Combination of picotamide with nafronyl |